| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/04/2013 | WO2013098420A1 Method of isolating human antibodies |
| 07/04/2013 | WO2013098419A1 Method of providing monoclonal auto-antibodies with desired specificity |
| 07/04/2013 | WO2013098364A1 Second generation virus-like particles (vlp) from epstein-barr viruses for vaccination purposes |
| 07/04/2013 | WO2013098214A1 A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv |
| 07/04/2013 | WO2013097838A1 Live attenuated salmonella enterica capm 6449 strain for oral vaccination of farm animal |
| 07/04/2013 | WO2013066780A3 Methods for reducing the frequency and severity of acute exacerbations of asthma |
| 07/04/2013 | WO2013055385A3 Methods of treating age related disorders |
| 07/04/2013 | WO2013046226A3 A novel quantification method for vaccines |
| 07/04/2013 | WO2013036904A3 Methods, agents and peptides for inhibiting matrix metalloproteinase-2 signaling |
| 07/04/2013 | WO2013019669A3 Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses |
| 07/04/2013 | WO2012048332A3 A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use |
| 07/04/2013 | US20130174288 Antibodies for the treatment of hiv |
| 07/04/2013 | US20130172656 Novel use of armillaridin for treating cancer |
| 07/04/2013 | US20130172279 Composition for topical treatment of mixed vaginal infections |
| 07/04/2013 | US20130171716 Animal product free system and process for purifying a botulinum toxin |
| 07/04/2013 | US20130171241 Liposomes with lipids having an advantageous pka-value for rna delivery |
| 07/04/2013 | US20130171238 Immunogenic compositions for chlamydia trachomatis |
| 07/04/2013 | US20130171234 Subunit Vaccines for Herpes Viruses and Methods of Use |
| 07/04/2013 | US20130171233 Compositions and methods for inducing immune tolerance |
| 07/04/2013 | US20130171193 Therapeutic vaccination against active tuberculosis |
| 07/04/2013 | US20130171192 Adjuvant formulations for bacterial and virus vaccines and method of making same |
| 07/04/2013 | US20130171191 Compositions and Methods for Enhancing Dendritic Cell Resistance to Bacterial Infection and for Enhancing the Mobility of Dendritic Cells for Dendritic Cell-Based Immunotherapy |
| 07/04/2013 | US20130171190 Regulated expression of antigen and/or regulated attentuation to enhance vaccine immunogenicity and/or safety |
| 07/04/2013 | US20130171189 Inducible and repressible vaccinia viruses with improved safety |
| 07/04/2013 | US20130171188 Immunogenic composition |
| 07/04/2013 | US20130171187 Glucan-based vaccines |
| 07/04/2013 | US20130171185 Norovirus derived immunogenic compositions and methods |
| 07/04/2013 | US20130171184 Vaccine against n. meningitidis |
| 07/04/2013 | US20130171183 Compositions and methods related to protein a (spa) variants |
| 07/04/2013 | US20130171181 Dps fusion proteins for use in vaccines and diagnostics |
| 07/04/2013 | US20130171178 Immunogenic Peptides of Xage-1 |
| 07/04/2013 | US20130171174 Anti-human epidermal growth factor receptor antibody and uses thereof |
| 07/04/2013 | US20130171173 Method for prongf assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of prongf |
| 07/04/2013 | US20130171172 Calpain-3 inhibitors for treating muscular dystrophies and cardiomyopathies |
| 07/04/2013 | US20130171168 Human Anti-OPGL Neutralizing Antibodies as Selective OPGL Pathway Inhibitors |
| 07/04/2013 | US20130171167 Methods of Using IL-1beta Compounds |
| 07/04/2013 | US20130171163 Inhibition of LAR Phosphatase to Enhance Therapeutic Angiogenesis |
| 07/04/2013 | US20130171162 Compositions and methods for the prevention of oxidative degradation of proteins |
| 07/04/2013 | US20130171161 Method and composition for the treatment of diseases caused by or associated with hiv |
| 07/04/2013 | US20130171160 Antibodies directed to angiopoietin-2 and uses thereof |
| 07/04/2013 | US20130171159 Phosphorylated twist1 and metastasis |
| 07/04/2013 | US20130171157 NOGO Receptor-Mediated Blockade of Axonal Growth |
| 07/04/2013 | US20130171156 BMP-1 Procollagen C-Proteinase for Diagnosis and Treatment of Bone and Soft Tissue Defects and Disorders |
| 07/04/2013 | US20130171155 Inhibitors Of Complement Activation |
| 07/04/2013 | US20130171149 Anti-ANGPTL3 Antibodies and Uses Thereof |
| 07/04/2013 | US20130171146 Dual-specific il-1a/ il-1b antibodies |
| 07/04/2013 | US20130171144 Anti-factor xi monoclonal antibodies and methods of use thereof |
| 07/04/2013 | US20130171142 Methods of using anti-cd3 antibodies to prevent weight gain |
| 07/04/2013 | US20130171141 Combination of hdac inhibitors with thrombocytopenia drugs |
| 07/04/2013 | US20130171139 Ncam-vase and neurodegeneration |
| 07/04/2013 | US20130171138 Immunoglobulin Chimeric Monomer-Dimer Hybrids |
| 07/04/2013 | US20130171137 Methods of treating autoimmune diseases with anti-fceri antibodies |
| 07/04/2013 | US20130171136 Methods of Treating Giant Cell Arteritis With Anti-TNF Alpha Antibodies |
| 07/04/2013 | US20130171135 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| 07/04/2013 | US20130171134 Neuropilin as a biomarker for bevacizumab combination therapies |
| 07/04/2013 | US20130171133 Cancer methods |
| 07/04/2013 | US20130171105 Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor |
| 07/04/2013 | US20130171103 Methods for treating viral conditions |
| 07/04/2013 | US20130171096 Immunobinders directed against sclerostin |
| 07/04/2013 | US20130171074 Targeting compounds |
| 07/04/2013 | US20130171063 Antibodies Directed to the Unprocessed Receptor Tyrosine Kinase c-Met |
| 07/04/2013 | US20130171059 Dual variable domain immunoglobulins and uses thereof |
| 07/04/2013 | DE112011102412T5 Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von mit Atemwegserkrankungen bzw. Atemwegsleiden assoziierten Erkrankungen bzw. Leiden A pharmaceutical combination composition and method for the treatment of conditions associated with respiratory diseases and respiratory ailments diseases or conditions |
| 07/04/2013 | CA2855182A1 Pharmaceutical compositions for the treatment of tumours that express egfr and ganglioside n-glycolyl gm3 (neugcgm3) |
| 07/04/2013 | CA2854594A1 Antigens and vaccines directed against human enteroviruses |
| 07/03/2013 | EP2610345A1 Recombinant influenza virus-like particles (VLPS) produced in transgenic plants expressing hemagglutinin |
| 07/03/2013 | EP2610267A1 Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases |
| 07/03/2013 | EP2609932A2 Variant target binding agents and uses thereof |
| 07/03/2013 | EP2609931A1 Immunogenic composition |
| 07/03/2013 | EP2609920A1 Method of treating cancer by a combined therapy of YM-155 with other anticancer agents |
| 07/03/2013 | EP2609118A2 Anti-ox40 antibodies and methods of using the same |
| 07/03/2013 | EP2609117A1 Antibodies against il-18r1 and uses thereof |
| 07/03/2013 | EP2609113A1 Monoclonal antibody specific to major neutralizing epitope of influenza h5 hemagglutinin |
| 07/03/2013 | EP2608809A2 Antibodies to matrix metalloproteinase 9 |
| 07/03/2013 | EP2608808A2 Treatment for neoplastic diseases |
| 07/03/2013 | EP2608807A1 Notum protein modulators and methods of use |
| 07/03/2013 | EP2608806A1 An epstein-barr-virus vaccine |
| 07/03/2013 | EP2608805A2 STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS |
| 07/03/2013 | EP2608804A1 Treatment of renal diseases |
| 07/03/2013 | EP2608803A2 Dual variable domain immunoglobulins and uses thereof |
| 07/03/2013 | EP2608801A2 INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES |
| 07/03/2013 | EP2608799A2 Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| 07/03/2013 | EP2608780A1 Improved enteric active substance delivery |
| 07/03/2013 | EP2608774A1 Porous degradable polyelectrolyte microspheres as vaccine vector |
| 07/03/2013 | EP2608661A1 Animal model for the evaluation of the efficacy of an hiv vaccine |
| 07/03/2013 | EP2207809B1 Heparin-binding epidermal growth factor-like growth factor antigen binding proteins |
| 07/03/2013 | CN1360678B Method for early detection of flaviviruses using NS1 glycoprotein and application thereof |
| 07/03/2013 | CN103189510A TTLL4 peptides and vaccines containing the same |
| 07/03/2013 | CN103189392A ErbB3 binding antibody |
| 07/03/2013 | CN103189387A Recombinant neisseria meningitidis Por A porin proteins |
| 07/03/2013 | CN103189386A Recombinant envelope protein of human immunodeficiency virus (hiv) and vaccine containing the same |
| 07/03/2013 | CN103189074A Methods of treating rheumatoid arthritis using IL-17 antagonists |
| 07/03/2013 | CN103189073A Antibodies against epidermal growth factor receptor (EGFR) and uses thereof |
| 07/03/2013 | CN103189072A Novel immunostimulatory method |
| 07/03/2013 | CN103189071A Stable formulations of neisseria meningitidis rLP2086 antigens |
| 07/03/2013 | CN103189050A Liposome-based construct comprising a peptide modified through hydrophobic moieties |
| 07/03/2013 | CN103184234A Tumor antigens BFA5 for prevention and/or treatment of cancer |
| 07/03/2013 | CN103184231A Vector used for displaying antigenic epitope by using hepatitis B virus core particles, animal vaccine, and preparation method thereof |
| 07/03/2013 | CN103184230A Fusion protein gene TAT-sVP7 and application thereof |
| 07/03/2013 | CN103184225A Taenia multiceps antigen gene and recombinant protein and application thereof |